RXII News 3.51 Rxi Pharmaceuticals (RXII)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rxi Pharmaceuticals (RXII) 3.51 $RXII

RXi Pharmaceuticals Reports Full Year 2013 Financial Results
PR Newswire - Fri Mar 28, 3:45PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

RXi Pharmaceuticals Announces Upcoming Presentations
PR Newswire - Fri Mar 14, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced upcoming presentations at the 6th Ocular Diseases and Drug Development Conference, the 72nd Annual Meeting of the American Academy of Dermatology ("AAD" and the Keystone Symposia Meeting, Fibrosis: From Bench to Bedside.

RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
PR Newswire - Wed Mar 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has been granted a patent by the U.S. Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI--109, for the treatment of fibrotic disorders. U.S. Patent Number 8,664,189, will expire in 2029. The Notice of Allowance was released on January 14, 2014 for this patent.

RXi Pharmaceuticals to Present at the 26th Annual ROTH Conference
PR Newswire - Tue Mar 04, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 4:30pm PST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

RXi Pharmaceuticals (RXII) Jumps: Stock Adds 28.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
RXi Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 29% on the day.

RXi Pharmaceuticals to Present at the 24th Annual Wall Street Analyst Forum
PR Newswire - Mon Feb 24, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 24th Annual Wall Street Analyst Forum on Monday, March 3, 2014 at 12:50pm EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

OTC Markets Group Congratulates RXI Pharmaceuticals on NASDAQ Listing
PR Newswire - Tue Feb 11, 9:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM) congratulates RXI Pharmaceuticals Corp. (NASDAQ: RXII) on its approval to list on the NASDAQ Capital Market. RXI is moving to NASDAQ from OTCQX®, the best marketplace for qualified companies.

RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market
PR Newswire - Tue Feb 11, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ" Listing Qualification Department to list its common stock on the NASDAQ Capital Market. The Company's common stock will commence trading under the same ticker symbol, "RXII," on the NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014.

RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 03, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30am EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics
ACCESSWIRE - Fri Jan 24, 9:06AM CST
RNA interference ("RNAi" therapeutics may have experienced some hurdles in the past, but favorable clinical results have boosted their profile in recent months. With new data supporting both safety and efficacy, larger pharmaceutical companies are starting to regain confidence in the sector. These dynamics have sparked a number of new deals and collaborations that have boosted industry valuations and opened the door to new opportunities.

RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
PR Newswire - Tue Jan 14, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.

NIH Data Sharing Projects Could Accelerate RNAi Field
ACCESSWIRE - Wed Jan 08, 10:16AM CST
The RNA industry could receive a significant boost this year after the National Institute of Health ("NIH" announced a data-sharing collaboration with Life Technologies Corp. (NASDAQ: LIFE) in December. Under the deal, large-scale information covering the biochemical makeup of small interfering RNA ("siRNA" molecules will be made publicly available to help scientists better understand how genes affect disease.

RXi Pharmaceuticals to Present at the Biotech Showcase(TM) 2014
PR Newswire - Mon Jan 06, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the Biotech Showcase(TM) 2014 conference on Tuesday, January 14, 2014 at 9:30AM PST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd--rxRNA® technology platform.

Surgical Scar Market Is Ripe for Innovation
ACCESSWIRE - Wed Dec 18, 10:15AM CST
Scarring is an inevitable consequence of dermal wounds - such as those incurred during routine surgeries - that has a profound impact on physical appearance and psychological well-being. Despite high demand for therapies that prevent or reduce dermal scarring, there are few treatment options approved by the U.S. Food & Drug Administration ("FDA", which has led to significant investor appetite for companies targeting the space. For instance, Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) recently doubled in price after receiving FDA 510(k) approval for its Microcyn Scar Management HydroGel on December 4, 2013.

RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
PR Newswire - Wed Dec 04, 7:05AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced additional results from their second placebo-controlled Phase 1 study with RXI--109, an sd-rxRNA® compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

RXi Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference
PR Newswire - Wed Nov 27, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's Chief Development Officer, Dr. Pamela Pavco, will present at the Piper Jaffray 25th Annual Healthcare Conference on Wednesday, December 4, 2013 at 12:00 pm EST at The New York Palace Hotel in New York, NY. Dr. Pavco will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

RXi Pharmaceuticals and Ethicor signs distribution agreement for RXI-109 in the EU
M2 - Tue Nov 19, 5:29AM CST
Biotechnology company RXi Pharmaceuticals Corporation (OTC: RXII) announced on Monday the signing of a distribution agreement with Ethicor Ltd, a UK based unlicensed medicinal products (Specials) pharmaceutical company.

RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
PR Newswire - Mon Nov 18, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that they have signed a distribution agreement with Ethicor Ltd., a UK based unlicensed medicinal products ("Specials" pharmaceutical company. The agreement provides Ethicor with the distribution rights to RXI-109 in the European Union, with the possibility to extend it to other regions of the world, excluding the United States, Canada and Mexico, prior to and until the registration of the product in the different countries covered by the agreement.

RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
PR Newswire - Thu Nov 14, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the quarter ended September 30, 2013, and provided a business update.

Today's Reviews on APDN, FTTN, APPA and RXII
ACCESSWIRE - Thu Nov 14, 4:07AM CST
Today's reviewed stocks include Applied DNA Sciences Inc. (OTC:APDN), First Titan Corp. (OTC:FTTN), AP Pharma Inc. (OTC:APPA) and RXi Pharmaceuticals Corporation (OTC:RXII).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 154

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 67

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 158

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 251

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 337

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 143

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Impact of Proposed Tariffs on Europe's Automotive Sector

Updated Category News Views 226

Understanding the Impact of Proposed Tariffs on the Auto Industry The recent political climate and proposed tariffs from former U.S. President Donald Trump signal significant changes ahead for global automakers. European car manufacturers, including giants like Volkswagen and Stellantis, may feel the ripple effects more acutely than expected. This article explores how...

Continue Reading
Corning Incorporated Reports Impressive Year-End Results

Updated Category News Views 431

Corning Incorporated's Remarkable Financial Performance Corning Incorporated (NYSE: GLW) has announced impressive financial outcomes for the fourth quarter and full year 2024. The results reflect the company's successful implementation of its 'Springboard' plan and position Corning for continuous growth as it enters 2025. Outstanding Fourth-Quarter Growth In the fourth...

Continue Reading
AAV Gene Therapy Landscape: Transforming Retinal Disease Treatments

Updated Category News Views 199

Introducing the AAV Gene Therapy for Retinal Diseases Adeno-associated virus (AAV) has emerged as an essential tool in the realm of gene therapy, particularly for treating hereditary retinal diseases caused by mutations in critical genes such as RPE65, CEP290, and CHM. This gene therapy approach is designed to address unmet medical needs, offering hope for long-term or...

Continue Reading
Rayonier Declares 4th Quarter Dividend and Company Outlook

Updated Category News Views 76

Rayonier Announces Fourth-Quarter Dividend Rayonier Inc. (NYSE: RYN), a prominent timberland real estate investment trust (REIT), has declared an impressive quarterly cash dividend of $0.285 per common share. Shareholders can expect this dividend to be paid on December 31, 2024, to those recorded by December 17, 2024. This announcement reflects Rayonier's dedication to...

Continue Reading
Cango Inc. Reports Record Financial Growth and Future Plans

Updated Category News Views 177

Cango Inc. Financial Highlights Cango Inc. (NYSE: CANG) a prominent name in Bitcoin mining and automotive transaction services, has released its unaudited financial results demonstrating significant achievements in the financial year. Robust Fourth Quarter Performance The fourth quarter of 2024 was particularly fruitful for Cango, showcasing total revenues of RMB668...

Continue Reading